Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration

Akuffo, K. O. and Nolan, J. M. and Howard, A. N. and Moran, R. and Stack, J. and Klein, R. and Klein, B. E. and Meuer, S. M. and Sabour-Pickett, S. and Thurnham, D. I. and Beatty, S. (2015) Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration. Eye (Basingstoke), 29 (7). pp. 902-912. ISSN 0950-222X

Full text not available from this repository. (Request a copy)

Abstract

PurposeTo compare the impact of sustained supplementation using different macular carotenoid formulations on macular pigment (MP) and visual function in early age-related macular degeneration (AMD).Patients and methodsSixty-seven subjects with early AMD were randomly assigned to: Group 1 (20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein), Group 2 (10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2 mg per day Z; Macushield; Macuhealth), Group 3 (17 mg per day MZ, 3 mg per day L, 2 mg per day Z). MP was measured using customised heterochromatic flicker photometry and visual function was assessed by measuring contrast sensitivity (CS) and best-corrected visual acuity (BCVA). AMD was graded using the Wisconsin Age-Related Maculopathy Grading System (AREDS 11-step severity scale).ResultsAt 3 years, a significant increase in MP from baseline was observed in all groups at each eccentricity (P<0.05), except at 1.75° in Group 1 (P=0.160). Between 24 and 36 months, significant increases in MP at each eccentricity were seen in Group 3 (P<0.05 for all), and at 0.50° in Group 2 (P<0.05), whereas no significant increases were seen in Group 1 (P>0.05 for all). At 36 months, compared with baseline, the following significant improvements (P<0.05) in CS were observed: Group 2 - 1.2, 6, and 9.6 cycles per degree (c.p.d.); Group 1 - 15.15 c.p.d.; and Group 3 - 6, 9.6, and 15.15 c.p.d. No significant changes in BCVA, or progression to advanced AMD, were observed.ConclusionIn early AMD, MP can be augmented with a variety of supplements, although the inclusion of MZ may confer benefits in terms of panprofile augmentation and in terms of CS enhancement.

Item Type:	Article
Additional Information:	Funding Information: This study was funded by a grant from the Howard Foundation, Cambridge, UK. KOA and JMN (the principal investigator) are currently funded by the European Research Council (ERC), grant reference number: 281096. We would like to thank Industrial Orgánica and Macuvision Europe for providing the study supplements. Publisher Copyright: © 2015 Macmillan Publishers Limited.
Uncontrolled Keywords:	/dk/atira/pure/subjectarea/asjc/2700/2731
Departments or Groups:
Depositing User:	Admin SSL
Date Deposited:	19 Oct 2022 23:10
Last Modified:	07 Jul 2023 16:05
URI:	http://repository-testing.wit.ie/id/eprint/4517

Actions (login required)

View Item